Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.A-CUBE has reached an agreement with Chugai Pharmaceutical in Japan to collaborate on developing the next generation of antibody therapeutics using A-CUBE's proprietary in silico algorithms.
Subscribe to our email newsletter
A-CUBE is a venture capital-backed company funded by JAIC and yet2.com, which uses proprietary in silico algorithms to predict and monetize novel drug targets related to blockbuster drugs.
A-CUBE has used this to develop a preclinical therapeutic monoclonal antibody for cancer and other diseases.
A-CUBE founder and president Nobu Ota we are very pleased to start this collaboration with Chugai, Japan’s leading pharmaceutical company, and a leader in monoclonal antibody therapeutics.
Chugai Research Division vice president and general manager Hisafumi Okabe said A-CUBE brings very original approaches that are complementary to Chugai’s own capabilities.
"We are expecting that they can make contributions to our challenge in this much competitive area of research," Okabe said.